BioPharmSignal logoBioPharmSignal

Biotech News

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

electroCore (ECOR)electroCoreEarnings

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.

Related news

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

TNXPTonix Pharmaceuticals2026-10-26 11:00 EST

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

ALKSAlkermes plc2026-10-20 20:00 EST

Alkermes to Report Third Quarter Financial Results on November 3, 2026

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

View all latest news

electroCore

Noninvasive Neuromodulation electroCore develops handheld bioelectronic devices that stimulate the vagus nerve without surgery. Its products are used across prescription and consumer channels. gammaCore gammaCore is a prescription noninvasive vagus-nerve-stimulation device used for headache disorders. A major commercial channel is the...

Recent company news

ECORelectroCore2026-11-05 13:00 EST

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ECORelectroCore2026-10-29 12:00 EST

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

ECORelectroCore2026-10-28 12:00 EST

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

ECORelectroCore2026-10-27 12:00 EST

fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning

ECORelectroCore2026-10-21 12:00 EST

electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub

Stock data

Close
8.80 USD
Market cap
78.39M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States